# reload+after+2024-01-22 13:47:59.557919
address1§2600 Kelly Road
address2§Suite 100
city§Warrington
state§PA
zip§18976-3622
country§United States
phone§215 488 9300
website§https://windtreetx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
fullTimeEmployees§20
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Craig E. Fraser', 'age': 58, 'title': 'Chairman, President, CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 553750, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steven G. Simonson', 'age': 64, 'title': 'Senior VP & Chief Medical Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 446102, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John A. Tattory', 'age': 57, 'title': 'Interim Chief Financial Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 496866, 'exercisedValue': 0, 'unexercisedValue': 7383}, {'maxAge': 1, 'name': 'Mr. Eric L. Curtis M.B.A.', 'age': 55, 'title': 'Senior VP & COO', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 526246, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jamie  McAndrew', 'age': 43, 'title': 'VP, Controller & Chief Accounting Officer', 'yearBorn': 1980, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. George  Cox', 'age': 71, 'title': 'Vice President of Technical Operations', 'yearBorn': 1952, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Pratap  Paruchuru', 'title': 'Executive Director of Clinical Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tracy  Rarick', 'title': 'Head of Operations & Program Management', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.595
currency§USD
dateShortInterest§1702598400
forwardEps§-0.97
exchange§NCM
quoteType§EQUITY
shortName§Windtree Therapeutics, Inc.
longName§Windtree Therapeutics, Inc.
firstTradeDateEpochUtc§807802200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a8ce5c24-4569-300c-8c4b-42b73b0377f8
gmtOffSetMilliseconds§-18000000
targetHighPrice§5.0
targetLowPrice§1.0
targetMeanPrice§3.0
targetMedianPrice§3.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§1.986
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
